OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS

Leijen S.; Barlesi F.; Eberhardt W. E. E.; Martinez G. M.; Dieras V.; Schellens J. H. M.; Middleton Mr; Calvo E.; Paz-Ares L.; Larkin J.; Jodrell D.; Soria J. C.

首页> 外文期刊>British Journal of Clinical Pharmacology >OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS

【24h】

OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS

机译：MEK抑制剂RO4987655（CH4987655）在单剂治疗中观察到的眼毒性我在高级实体瘤患者中进行了研究并进行了扩展

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《British Journal of Clinical Pharmacology》 |2014年第4期|共1页
作者
Leijen S.; Barlesi F.; Eberhardt W. E. E.; Martinez G. M.; Dieras V.; Schellens J. H. M.; Middleton Mr; Calvo E.; Paz-Ares L.; Larkin J.; Jodrell D.; Soria J. C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
入库时间 2022-08-18 09:14:17

相似文献

外文文献
专利

1. OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS [J] . Leijen S., Barlesi F., Eberhardt W. E. E., British Journal of Clinical Pharmacology . 2014,第4期

机译：MEK抑制剂RO4987655（CH4987655）在单剂治疗中观察到的眼毒性我在高级实体瘤患者中进行了研究并进行了扩展
2. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors [J] . Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第17期

机译：MEK抑制剂RO4987655（CH4987655）在晚期实体瘤患者中的安全性，药代动力学和药效学的I期剂量递增研究
3. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations [J] . ZimmerL., BarlesiF., Martinez-GarciaM., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第16期

机译：MEK抑制剂RO4987655（CH4987655）在某些患有RAS-RAF突变的晚期癌症患者中的I期扩展和药效学研究
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase Ib/II open-label dose-escalation study of LGX818 an oral selective BRAF inhibitor in combination with MEK162 an oral MEK1/2 inhibitor in patients with BRAF V600-dependent advanced solid tumors: preliminary results [O] . Richard Kefford, Ryan J Sullivan, Wilson H Miller Jr, 2014

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的BRAF V600依赖性晚期实体瘤患者的Ib / II期开放标签剂量递增研究：初步结果
7. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. [O] . Leijen, S, Middleton, MR, Tresca, P, 2012

机译：I期剂量递增研究对晚期实体瘤患者MEK抑制剂RO4987655（CH4987655）的安全性，药代动力学和药效学进行了研究。

OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS

著录项

相似文献

相关主题

期刊订阅